NBDC Research ID: hum0292.v1

SUMMARY

Aims: To develop predictive biomarkers for the treatment of castration-resistant prostate cancer (CRPC) such as abiraterone, enzalutamide, docetaxel, and cabazitaxel based on genomic analyses of cell-free DNA (cfDNA) and circulating tumor cells (CTC).

Methods: One hundred CRPC patients eligible for treatment with either abiraterone or enzalutamide were prospectively enrolled at 17 institutions in Japan. cfDNA and paired lymphocyte DNA per patient were used for sequencing library preparation, and unique molecular identifiers were added. Targeted sequencing was performed using Illumina NovaSeq (Our custom gene panel captures the exonic regions of 88 genes).

Participants/Materials: 100 CRPC patients eligible for abiraterone or enzalutamide

Data Set ID	Type of Data	Criteria	Release Date
JGAS000330	NGS (Target Capture)	Controlled Access (Type I)	2021/09/24

*Release Note

*Data users need to apply an application for Using NBDC Human Data to reach the Controlled-access Data. Learn more

JGAS000330


Participants/Materials	CRPC patients eligible for abiraterone or enzalutamide (ICD10: C61): 100 cases
Targets	Target Capture
Target Loci for Capture Methods	88 genes
Platform	Illumina [NovaSeq 6000]
Library Source	cfDNA and paired lymphocyte DNA extracted from peripheral blood
Cell Lines	-
Library Construction (kit name)	ThruPLEX tag-seq, KAPA HyperChoice Probes
Fragmentation Methods	Ultrasonic fragmentation (Covaris)
Spot Type	Paired-end
Read Length (without Barcodes, Adaptors, Primers, and Linkers)	150 bp
Japanese Genotype-phenotype Archive Data set ID	JGAD000441
Total Data Volume	1.8 TB (fastq)
Comments (Policies)	NBDC policy

DATA PROVIDER

Principal Investigator: Shusuke Akamatsu

Affiliation: Department of Urology, Graduate School of Medicine, Kyoto University

Project / Group Name: -

Funds / Grants (Research Project Number):

Name	Title	Project Number
KAKENHI Grant-in-Aid for Scientific Research (B)	Understanding the biological mechanisms of defective DNA damage repair in prostate cancer using cell-free DNA analysis	20H03814
AstraZeneca Externally Sponsored Scientific Research	The prevalence of germline and somatic DNA repair gene mutations in Japanese prostate cancer patients	ESR I: NCR-17-13159
Astellas Research Grant	Identification of factors predicting response to enzalutamide using tissues of castration-resistant prostate cancer	-

PUBLICATIONS

	Title	DOI	Data Set ID
1	Clinical Impact of Detecting Low-Frequency Variants in Cell-Free DNA on Treatment of Castration-Resistant Prostate Cancer	doi: 10.1158/1078-0432.CCR-21-2328	JGAD000441
2

USRES (Controlled-Access Data)

Principal Investigator	Affiliation	Research Title	Data in Use (Data Set ID)	Period of Data Use